Stifel Maintains Buy on DarioHealth, Lowers Price Target to $2

Benzinga · 03/11 12:43
Stifel analyst David Grossman maintains DarioHealth (NASDAQ:DRIO) with a Buy and lowers the price target from $3.5 to $2.